Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | TGM2 | P21980 | 7/20 | 0.40 |
| ▸ | F13A1 | P00488 | 6/20 | 0.40 |
| ▸ | TGM1 | P22735 | 6/20 | 0.40 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888393 | 0.88 | POLB (0.52) | KDM4EMAPTFPR2GPR119PKM | |
| SCHEMBL6893849 | 0.83 | MMP13 (0.46) | KDM4EMAPTFPR2GPR119 | |
| SCHEMBL6896081 | 0.82 | FPR2 (0.42) | KDM4EFPR2GPR119TGM2F13A1 | |
| SCHEMBL6894313 | 0.79 | TGM2 (0.46) | FPR2GPR119TGM2F13A1TGM1 | |
| SCHEMBL4388695 | 0.79 | F10 (0.54) | — | |
| SCHEMBL6895742 | 0.78 | GPR119 (0.46) | FPR2GPR119TGM2F13A1TGM1 | |
| SCHEMBL6894470 | 0.78 | GPR119 (0.46) | FPR2GPR119TGM2F13A1TGM1 | |
| SCHEMBL6896691 | 0.77 | FPR2 (0.42) | KDM4EFPR2GPR119PKM | |
| SCHEMBL6895107 | 0.77 | TGM2 (0.49) | FPR2GPR119TGM2F13A1TGM1 | |
| SCHEMBL6895113 | 0.77 | TGM2 (0.49) | FPR2GPR119TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | KDM4E 1392/4885MAPT 4851/4885FPR2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.